provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeWell-beingSubstance Use

What Is Microdosing? Benefits, Effects, Safety, and More

Sarah Gupta, MDFarzon A. Nahvi, MD
Written by Sarah Gupta, MD | Reviewed by Farzon A. Nahvi, MD
Updated on July 16, 2025

Key takeaways:

  • Microdosing is the practice of consuming very small amounts of psychedelics — substances that can produce hallucinations.

  • There’s not enough evidence yet to say whether microdosing has any benefits. More research is needed to know if microdosing is useful for mental and physical health.

  • Although microdosing may seem interesting, keep in mind that taking psychedelics has risks and that the substances are illegal on the federal level.

A person using their phone on a bean bag chair.
Wavebreakmedia/iStock via Getty Images Plus

Many people are searching for ways to feel better, be happier, and gain more from life. With this in mind, some people are experimenting with microdosing psychedelics, including LSD and psilocybin (“magic mushrooms”). 

Microdosing is the popular trend of taking a small amount of a psychedelic drug — an amount low enough that it doesn’t cause hallucinations. Some people feel like microdosing might boost their mood, focus, and creativity. 

Microdosing is getting a lot of attention in the media. But here’s the reality: There just isn’t enough evidence yet to say if microdosing is beneficial — or even safe. And psychedelics are still illegal in the U.S. 

Search and compare options

Search is powered by a third party. By clicking a topic in the advertisement above, you agree that you will visit a landing page with search results generated by a third party, and that your personal identifiers and engagement on this page and the landing page may be shared with such third party. GoodRx may receive compensation in relation to your search.

What is microdosing?

Microdosing is the practice of taking a small amount of a psychedelic drug — like LSD or psilocybin — on a fixed schedule. Psychedelics commonly used for personal use (“recreational” use) include:

  • LSD

  • Psilocybin (“magic mushrooms”)

  • Ayahuasca

  • Mescaline

  • MDMA (ecstasy)

  • Ketamine

People are experimenting with microdosing these psychedelics, and advocates say the practice helps with mood and well-being. But the research needs to catch up, and healthcare professionals and scientists aren’t convinced yet.

Potential benefits of microdosing

It’s not clear what the true benefits of microdosing are. Researchers know that psilocybin-assisted therapy can be an effective treatment for mental health conditions like depression. However, they aren’t yet sure if microdosing works the same way. 

Some studies report that people who microdose can have the following benefits:

  • Improved mood

  • Lower anxiety

  • Clearer thinking abilities

  • More focus and motivation

  • Decreased substance use

  • Increased sense of well-being

GoodRx icon
  • Psilocybin and your health: Psilocybin is the active chemical in “magic mushrooms.” Here’s how it affects the mind and body and what research shows about its potential health benefits.

  • LSD and mental health therapy: LSD is another psychedelic drug that causes changes in mood and perception. Here are the uses scientists are studying.

  • Ketamine and depression: Ketamine has been used in medicine for different reasons over the decades. Learn more about the growing research on ketamine as a treatment for depression.

But the evidence is mixed. The data showing benefits of microdosing is often only based on self-reported symptoms, which can be biased. And some people who microdose also report higher anxiety and lower mood.

There’s also some evidence that microdosing may work for migraines and cluster headaches. But many consider microdosing to be a last-resort treatment option. 

Similarly, preliminary research has shown some potential benefit from microdosing for attention-deficit hyperactivity disorder (ADHD). But in a 2025 randomized controlled trial, there was no difference in ADHD symptoms between a placebo group and a group that took microdoses of LSD. 

There may be a large placebo effect with microdosing. This means that people who expect an effect from the microdosing seem to notice the most benefit. More clinical trials are needed to help to distinguish a placebo effect from actual health benefits from microdosing. 

How much is a microdose?

Researchers generally consider a microdose to be a dose that doesn’t impair functioning and doesn’t cause hallucinations. Here’s what that may look like: 

  • LSD: A typical hallucinogenic dose of LSD might be 100 mcg to 200 mcg, and a microdose would be about 5 mcg to 20 mcg. 

  • Psilocybin (“magic mushrooms”): A typical hallucinogenic dose of psilocybin might be about 2.5 g, and a microdose would be 100 mg to 200 mg of dried psilocybin mushrooms.

The goal is to take enough to have potential benefits — but without causing someone to hallucinate or feel “high.” 

What is a typical microdosing schedule?

There are a few common microdosing schedules that people tend to follow. Typical microdosing schedules include:

  • Microdoses for 2 days, then 2 days without

  • Every other day use

  • Microdoses Monday to Friday, but not on weekend days

There’s no evidence to support any one microdosing schedule over another. Some people may choose to microdose every day, but that’s not very common. That’s because it’s believed that microdosing can have a lasting effect, and daily dosing isn’t necessary. 

There’s also a risk of developing a tolerance to the substance with frequent microdosing. This means your body can get used to the frequent microdosing and may need higher doses to have an effect. 

How long does microdosing last? 

Many people choose to make up their own microdosing routine based on their results. On average, microdosing can last for 1 week and up to 2 years or more. Most people stop microdosing when they feel they’re no longer getting the desired effect.

Is microdosing safe?

Microdosing is generally regarded as having a low risk of negative side effects. But there isn’t enough scientific evidence yet to say whether microdosing is safe.

One of the biggest challenges with microdosing is that most people aren’t sure if they’re getting the proper dose. It’s hard to know exactly how much of the substance you have in each dose, and it’s possible to take higher doses than intended. This is a common reason for negative side effects as well.

Possible negative side effects of microdosing

In one small survey, some of the challenges people experienced when microdosing included:

  • Problems paying attention

  • Problems thinking clearly (brain fog)

  • Low energy

  • Low mood

  • More anxiety

  • Appetite changes

  • Upset stomach 

  • Migraines and headaches 

  • Uncomfortable physical sensations, like numbness or tingling

  • Difficulty in social settings

  • Unwanted “trips” or hallucinations

Microdosing also carries the potential legal consequences of buying, possessing, and using these substances. Plus, when you get a substance from an unregulated source, you can’t be sure of the contents, contaminants, or potency.

Are psychedelics legal?

Psychedelics are illegal in the U.S. under federal law. But some states and cities have passed laws to decriminalize certain psychedelic drugs. Decriminalization usually means there are no harsh criminal penalties for people who have or use a decriminalized substance. 

Some states are also paving the way for the use of psychedelics as medical treatment. For example, in 2020 Oregon became the first state to approve psilocybin-assisted therapy in supervised healthcare facilities

Frequently asked questions

What are the long-term effects of microdosing mushrooms?

Reports on the side effects of microdosing psilocybin (magic mushrooms) vary widely. There’s limited data on possible long-term effects and prolonged use of microdosing psychedelics. This is because most studies look at single doses. 

But most side effects seem to be mild and short-lived. A temporary increase in blood pressure, anxiety, and cognitive functioning seem to be the most common. 

What is psychedelic-assisted therapy?

Psychedelic-assisted therapy involves the use of psychedelics along with therapeutic practices under the supervision of physicians, psychologists, or other trained professionals. There’s ongoing research on the potential of psychedelics like MDMA and psilocybin to help with symptoms of post-traumatic stress disorder (PTSD), anxiety, depression, and existential distress.

What are magic mushroom gummies, and are they safe?

There are many products on the market that claim to contain ingredients that can support cognitive health, including “magic mushroom gummies.” But these products can contain ingredients that aren’t listed on the package, which presents a serious public health risk

Can microdosing make you more depressed?

It’s possible that microdosing hallucinogens like psilocybin can worsen symptoms of depression for some people. There’s research to show that larger, hallucinogenic doses (macrodosing) can improve depression symptoms. But it’s not yet clear if microdosing has the same effect. If you’re curious about how microdosing may benefit you, it’s best to work with a healthcare professional who has training in psychedelic therapy. 

The bottom line

Despite the attention around microdosing and the popularity of the practice, it’s too early to know its full impact. More research will help uncover more information so experts can better understand how microdosing may be used for some health conditions. But for now, the risks and legal concerns are real, and they may outweigh the potential benefits. 

Keep in mind that psychedelics are legal in some states for personal and/or medicinal use, but not in others. Psilocybin and LSD are still illegal under federal law.

why trust our exports reliability shield

Why trust our experts?

Sarah Gupta, MD
Written by:
Sarah Gupta, MD
Sarah Gupta, MD, is a licensed physician with a special interest in mental health, sex and gender, eating disorders, and the human microbiome. She is currently board certified by the American Board of Psychiatry and Neurology.
Alex Eastman, PhD, RN
Alex Eastman, PhD, RN, is a California-based registered nurse and staff medical editor at GoodRx, where he focuses on clinical updates and Latino health.
Farzon A. Nahvi, MD
Dr. Nahvi is an emergency medicine physician and author of “Code Gray: Death, Life, and Uncertainty in the ER.” He works clinically at Concord Hospital in Concord, New Hampshire, and is a clinical assistant professor of emergency medicine at the Geisel School of Medicine at Dartmouth. Prior to this, he worked as an ER physician and clinical assistant professor of emergency medicine at the Mount Sinai Health System, NYU Langone Health, NYC Health + Hospitals/Bellevue, and the Manhattan VA. He is a graduate of Cornell University and NYU School of Medicine.

References

Anderson, T., et al. (2019). Psychedelic microdosing benefits and challenges: An empirical codebook. Harm Reduction Journal

Andersson, M., et al. (2017). Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal

View All References (23)

Haijen, E. C. H. M., et al. (2022). Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study. Neuroscience Applied.

Hutten, N. R. P. W., et al. (2019). Motives and side-effects of microdosing with psychedelics among users. International Journal of Neuropsychopharmacology.

Johnstad, P. G. (2018). Powerful substances in tiny amounts: An interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs.

Joseph, B. (2024). State lawmakers’ interest in psychedelic drugs not waning. LexisNexis. 

Kinderlehrer, D. A. (2025). Mushrooms, microdosing, and mental illness: The effect of psilocybin on neurotransmitters, neuroinflammation, and neuroplasticity. Neuropsychiatric Disease and Treatment

Kuypers, K. P. C. (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology.

Kuypers, K. P. C. (2020). The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology

MacCallum, C. A., et al. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry

Michienzi, A., et al. (2024). Notes from the field: Schedule I substances identified in nootropic gummies containing Amanita muscaria or other mushrooms — Charlottesville, Virginia, 2023–2024. Centers for Disease Control and Prevention.

Modzelewski, S., et al. (2025). Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes. Neuropharmacology.

Morland, L., et al. (2025). PTSD: National center for PTSD. U.S. Department of Veterans Affairs.

Mueller, L., et al. (2025). Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: A randomized clinical trial. JAMA Psychiatry

National Center for Complementary and Integrative Health. (2024). Psilocybin for mental health and addiction: What you need to know. National Institutes of Health. 

Passie, T., et al. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics

Polito, V., et al. (2019). A systematic study of microdosing psychedelics. PloS One

Polito, V., et al. (2022). The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neuroscience & Biobehavioral Reviews.

Rootman, J. M., et al. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports.

Sabatier, J. (2021). Oregon’s psilocybin program starts to take shape. OPB.

Schindler, E. A. D., et al. (2022). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache: The Journal of Head and Face Pain

Schipper, S., et al. (2024). Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Cochrane Database of Systematic Reviews.

Smith, D. G. (2023). More people are microdosing for mental health. But does it work? The New York Times. 

van Elk, M., et al. (2021). Effects of psilocybin microdosing on awe and aesthetic experiences: A preregistered field and lab-based study. Psychopharmacology

Williams, J. B., et al. (2012). P-640 - the power of expectation bias. European Psychiatry.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

Subscribe and save.

Get prescription saving tips and more from GoodRx Health. Enter your email to sign up.

By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.